Cue Biopharma, INC Form 4 insider transactions

Shao-Lee Lin, Chief Executive Officer and a Director of Cue Biopharma, Inc., sold 58,258 shares of common stock on August 12, 2026.

James M Ahlers, Chief Financial Officer of Cue Biopharma, Inc., reported multiple transactions in common stock on July 30, 2026.

Shao-Lee Lin, Chief Executive Officer and a Director of Cue Biopharma, Inc., reported multiple transactions in common stock on June 1, 2026.

Dominique Christian Borie, Chief Medical Officer of Cue Biopharma, Inc., reported multiple transactions in common stock on July 13, 2026.

Pamela Garzone, a Director at Cue Biopharma, Inc., has been granted 21,800 Restricted Stock Units (RSUs) vesting over three years.

Cue Biopharma reports a restricted stock unit grant to Director Daniel A. Camardo, with vesting over three years.

Cue Biopharma reports a restricted stock unit grant to Director Pasha Sarraf, with vesting over three years.

Viola Mong Meehan, a Director at Cue Biopharma, Inc., was granted 21,800 Restricted Stock Units (RSUs) on July 9, 2026.

Michael Meluzio, VP, Principal Accounting Officer at Cue Biopharma, Inc., was granted restricted and performance stock units.

Ray Sumita, Chief Legal Compliance Officer and Corporate Secretary at Cue Biopharma, Inc., was granted restricted and performance stock units.

Cue Biopharma's CEO, Lin Shao-Lee, was granted restricted and performance stock units on July 9, 2026, as disclosed in a Form 4 filing.

Cue Biopharma, Inc. reports that Director Daniel A. Camardo acquired stock options on May 30, 2026, as detailed in a Form 4 filing.

Cue Biopharma CEO Shao-Lee Lin acquired pre-funded warrants and common stock warrants through a private placement.

Director Viola Mong Meehan was granted 1,626 stock options in Cue Biopharma, Inc. as part of standard equity compensation.

Cue Biopharma CEO Lin Shao-Lee acquired company stock and stock options on May 3, 2026, as detailed in a Form 4 filing.

Colin Sandercock, SVP and General Counsel of Cue Biopharma, Inc., reported the acquisition of stock options.

Cue Biopharma reports a stock option grant to Chief Business Officer Lucinda Warren, with vesting over four years.

Daniel G. Baker, Chief Development Officer at Cue Biopharma, Inc., has been granted 100,000 stock options with an exercise price of $0.29.

Cue Biopharma Director Peter A Kiener was granted 24,400 stock options as part of the company's compensation policy.

Cue Biopharma's Director, Jill Marie Broadfoot, was granted 24,400 stock options as part of the company's compensation policy.

Cue Biopharma's Director, Pamela Garzone, was granted 24,400 stock options with an exercise price of $0.34, vesting on January 2, 2027.

Cue Biopharma Director Frank Morich received an award of 24,400 stock options with an exercise price of $0.34, exercisable in one year.

Cue Biopharma Director Patrick Verheyen was granted 24,400 stock options with an exercise price of $0.34, vesting on the first anniversary of the grant date.

Cue Biopharma's Director, Pasha Sarraf, was granted 24,400 stock options at an exercise price of $0.34, vesting in one year.

Cue Biopharma director Pasha Sarraf acquired 323,857 shares of common stock through multiple open market purchases.

Cue Biopharma's SVP, General Counsel, Colin Sandercock, saw 100,000 performance-based stock options vest at an exercise price of $0.7 per share.

Cue Biopharma's Chief Business Officer, Lucinda Warren, was granted 125,000 stock options with an exercise price of $0.72, exercisable one year from the grant date.

Cue Biopharma's Chief Development Officer, Daniel G. Baker, was granted 50,000 stock options with an exercise price of $0.72, effective September 29, 2025.

Cue Biopharma's CEO, Azam Usman, was granted 1.875 million stock options with an exercise price of $0.72, vesting over 48 months.

Cue Biopharma, Inc. Director Jill Marie Broadfoot has been granted 48,800 stock options as part of the company's Director Compensation Policy, aligning her interests with shareholder value.